Agendia is launching a patient access program to position MammaPrint in clinics, while other test makers are taking a wait-and-see approach.
The acquisition provides Myriad with the EndoPredict test, which is currently offered in Europe and is expected to launch in the US next year.
The analysis showed that one out of 227 node-negative breast cancer patients with the lowest EPclin scores by Sividon's EndoPredict test experienced recurrence over 10 years.
At the San Antonio Breast Cancer Symposium, a Sividon collaborator is scheduled to present a new study including a comparison between EndoPredict and Oncotype DX.
Matt Hancock, the UK health secretary, is calling for the swift rollout of predictive genetic tests, the Guardian reports.
A WHO panel is calling for a global registry of human germline gene-editing projects, according to Stat News.
Vox writes that lab mishaps involving pathogens are quite common.
In Genome Biology this week: analysis of wild and cultivated peach genomes, Hi-C-based pipeline for assembling microbial genomes from metagenomic data, and more.